Clinical trial
PI-88 in Hepatocellular Carcinoma After Hepatectomy
NCT00247728 · Cellxpert Biotechnology Corp., Industry · Completed
Key facts
| NCT number | NCT00247728 |
|---|---|
| Title | PI-88 in Hepatocellular Carcinoma After Hepatectomy |
| Official title | A Randomized, Multi-centre, Efficacy Evaluation of PI-88 in Patients With Hepatocellular Carcinoma After Hepatectomy - A Phase II Study |
| Lead sponsor | Cellxpert Biotechnology Corp., Industry |
| Collaborators | Medigen Biotechnology Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | PI-88 |
| Enrollment | 172 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 2, 2005 |
| Last update posted | Jun 23, 2022 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: